Peptide therapeutics for rare genetic metabolic diseases

Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Year Invested: 2010
Location: Boston, Mass.

Recent News

August 8, 2018
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

July 23, 2018
Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

June 20, 2018
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

Read More News

Associated Team Members

Neil Exter